TrialJournal of inherited metabolic disease2019

Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD).

Jerry Vockley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.